New insights in the management of pseudomyxoma peritonei

Abstract

AbstractWhile a rare entity, peritoneal pseudomyxoma treatment evolves. Decision‐making criteria improve with imaging development and exploratory laparoscopy. Surgery remains at the core of the therapeutic strategy whatever disease progression. Complete cytoreduction plus hyperthermic intraperitoneal chemotherapy (HIPEC) is standard of care. Iterative cytoreduction or debulking is sometimes justified. Intraperitoneal chemotherapy modalities change with early postoperative HIPEC or pressurized intraperitoneal aerosol chemotherapy. Systemic or local treatment such as new chemo/immuno‐therapies or BromAc should improve outcomes. Expertise and multicentric cooperation are more than ever needed.